Login Register Cart 0
Generic placeholder image

Current Pharmacogenomics and Personalized Medicine

Editor-in-Chief

ISSN (Print): 1875-6921
ISSN (Online): 1875-6913

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Association Study between rs10486567, rs13149290, rs1545985 and rs6983267 with Incidence of Prostate Adenocarcinoma Among Iranians

Author(s): Mina Allahverdi, Seyed Abdolhamid Angaji*, Behnaz Beikzadeh and Raheleh Roudi

Volume 21, Issue 1, 2024

Published on: 04 July, 2024

Page: [17 - 27] Pages: 11

DOI: 10.2174/0118756921287724240628080642

Price: $65

Abstract

Introduction: Prostate cancer is the second most frequent malignancy after lung cancer among men, accounting for 7% of new cancers diagnosed around the world (15% in developed regions). This disease has become more prevalent in Iran over the past few decades, moving up the rankings from 13th in 1986 to 4th in 2005 and finally reaching third place in a recent study in 2016. The purpose of this study is to investigate the association of rs10486567, rs13149290, rs6983267, and rs1545985 with prostate cancer predisposition in the Iranian population. Due to the genetic heterogeneity, each of the SNP should be studied separately in various communities.

Material and Methods: This study was conducted as a case-control study on 200 patients referred to Hashminejad Hospital in Tehran. 103 men with prostate adenocarcinoma were selected as case, and 97 men with benign prostatic hyperplasia (BPH) were selected as control. In this research, according to FAVORGENE-Taiwan extraction kit instructions, genomic DNA was extracted from peripheral blood lymphocytes Tetra-primer ARMS-PCR method was used for SNP genotyping.

Results: The significance level at the first stage was p-value≤0.4. rs10486567 (p-value = 0.802) and rs6983267 (p-value = 0.684). Based on the additive and multiplicative genetic model, no association of these polymorphisms with prostate adenocarcinoma was observed. As a result, rs10486567 and rs6983267 were removed at this stage. rs13149290 (p-value=0.4) and rs1545985 (p-value=0.4) at this stage were selected for the next stage. At the second stage rs13149290 (p-value=0.043) showed a significant difference in the comparison between the two groups, but this difference was not observed in relation to rs1545985 (p-value=0.392) rs1545985 was not associated with prostate adenocarcinoma in the additive genetic model. According to P=0.013 and OR (95% CI) =3.837 (1.306-11.268), rs13149290 polymorphism is associated with prostate adenocarcinoma in the additive genetic model (TT vs. CC).

Conclusion: As a result of this study, it was observed that rs13149290 is associated with prostate cancer in the Iranian population. Also this polymorphism is associated with Gleason score=7 and PSA ≤4. Prostate cancer as an exposure effect is heterogeneous between different PSA levels. It is suggested that this polymorphism be investigated in a larger population and in each ethnic group separately.

« Previous Next »
Graphical Abstract

[1]
Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers 2021; 7(1): 9.
[http://dx.doi.org/10.1038/s41572-020-00243-0] [PMID: 33542230]
[2]
Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: A review article. Iran J Public Health 2018; 47(3): 309-16.
[PMID: 29845017]
[3]
Roshandel G, Ferlay J, Ghanbari-Motlagh A, et al. Cancer in Iran 2008 to 2025: Recent incidence trends and short‐term predictions of the future burden. Int J Cancer 2021; 149(3): 594-605.
[http://dx.doi.org/10.1002/ijc.33574] [PMID: 33884608]
[4]
Dawam D, Rafindadi AH, Kalayi GD. Benign prostatic hyperplasia and prostate carcinoma in native Africans. BJU Int 2000; 85(9): 1074-7.
[http://dx.doi.org/10.1046/j.1464-410x.2000.00677.x] [PMID: 10848698]
[5]
Chan JM, Stampfer MJ, Giovannucci EL. Eds What causes prostate cancer? A brief summary of the epidemiology Seminars in cancer biology. Elsevier 1998.
[6]
Hickey K, Do KA, Green A. Smoking and prostate cancer. Epidemiol Rev 2001; 23(1): 115-25.
[http://dx.doi.org/10.1093/oxfordjournals.epirev.a000776] [PMID: 11588835]
[7]
Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118(10): 793-803.
[http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00007] [PMID: 8470854]
[8]
Shastry BS. SNPs in disease gene mapping, medicinal drug development and evolution. J Hum Genet 2007; 52(11): 871-80.
[http://dx.doi.org/10.1007/s10038-007-0200-z] [PMID: 17928948]
[9]
Robert F, Pelletier J. Exploring the impact of single-nucleotide polymorphisms on translation. Front Genet 2018; 9: 507.
[http://dx.doi.org/10.3389/fgene.2018.00507] [PMID: 30425729]
[10]
Marth GT, Korf I, Yandell MD, et al. A general approach to single-nucleotide polymorphism discovery. Nat Genet 1999; 23(4): 452-6.
[http://dx.doi.org/10.1038/70570] [PMID: 10581034]
[11]
Jacobs EJ, Hsing AW, Bain EB, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev 2008; 17(4): 972-7.
[http://dx.doi.org/10.1158/1055-9965.EPI-07-2787] [PMID: 18398039]
[12]
Allemailem KS, Almatroudi A, Alrumaihi F, et al. Single nucleotide polymorphisms (SNPs) in prostate cancer: Its implications in diagnostics and therapeutics. Am J Transl Res 2021; 13(4): 3868-89.
[PMID: 34017579]
[13]
Sung Y, Park S, Park SJ, et al. Jazf1 promotes prostate cancer progression by activating JNK/Slug. Oncotarget 2018; 9(1): 755-65.
[http://dx.doi.org/10.18632/oncotarget.23146] [PMID: 29416651]
[14]
Grisanzio C, Freedman ML. Chromosome 8q24–associated cancers and MYC. Genes Cancer 2010; 1(6): 555-9.
[http://dx.doi.org/10.1177/1947601910381380] [PMID: 21779458]
[15]
Alvidrez J, Castille D, Laude-Sharp M, Rosario A, Tabor D. The national institute on minority health and health disparities research framework. Am J Public Health 2019; 109(S1): S16-20.
[http://dx.doi.org/10.2105/AJPH.2018.304883] [PMID: 30699025]
[16]
Chen LS, Fann JCY, Chiu SYH, et al. Assessing interactions of two loci (rs4242382 and rs10486567) in familial prostate cancer: statistical evaluation of epistasis. PLoS One 2014; 9(2): e89508.
[http://dx.doi.org/10.1371/journal.pone.0089508] [PMID: 24586834]
[17]
Badrinarayanan L, Chitipothu S, Ramasubramanyan S, et al. Assessment of single nucleotide polymorphisms associated with steroid-induced ocular hypertension. Int J Ophthalmol 2020; 13(8): 1294-305.
[http://dx.doi.org/10.18240/ijo.2020.08.17] [PMID: 32821685]
[18]
Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99(24): 1836-44.
[http://dx.doi.org/10.1093/jnci/djm250] [PMID: 18073375]
[19]
Zhu M, Wen X, Liu X, Wang Y, Liang C, Tu J. Association between 8q24 rs6983267 polymorphism and cancer susceptibility: A meta-analysis involving 170,737 subjects. Oncotarget 2017; 8(34): 57421-39.
[http://dx.doi.org/10.18632/oncotarget.18960] [PMID: 28915683]
[20]
Prokunina-Olsson L, Hall JL. No effect of cancer-associated SNP rs6983267 in the 8q24 region on co-expression of MYC and TCF7L2 in normal colon tissue. Mol Cancer 2009; 8(1): 96.
[http://dx.doi.org/10.1186/1476-4598-8-96] [PMID: 19895682]
[21]
Zhu HS, Zhang JF, Zhou JD, Zhang MJ, Hu HX. Association between the 8q24 rs6983267 T/G polymorphism and prostate cancer risk: A meta-analysis. Genet Mol Res 2015; 14(4): 19329-41.
[http://dx.doi.org/10.4238/2015.December.29.43] [PMID: 26782586]
[22]
Cheng I, Plummer SJ, Neslund-Dudas C, et al. Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev 2010; 19(9): 2124-32.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-0268] [PMID: 20651075]
[23]
Olsvik HL, Lamark T, Takagi K, et al. FYCO1 contains a C-terminally extended, LC3A/B-preferring LC3-interacting region (LIR) motif required for efficient maturation of autophagosomes during basal autophagy. J Biol Chem 2015; 290(49): 29361-74.
[http://dx.doi.org/10.1074/jbc.M115.686915] [PMID: 26468287]
[24]
Gallagher DJ, Vijai J, Cronin AM, et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res 2010; 16(10): 2819-32.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-0028] [PMID: 20460480]
[25]
He Y, Gu J, Strom S, Logothetis CJ, Kim J, Wu X. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients. Clin Cancer Res 2014; 20(19): 5133-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0661] [PMID: 25274378]
[26]
Stevens VL, Ahn J, Sun J, et al. HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate 2010; 70(6): 601-7.
[http://dx.doi.org/10.1002/pros.21094] [PMID: 19998368]
[27]
Osman A, Ahmed AA, Elbagir AA. Single nucleotide polymorphism within chromosome 8q24 is associated with prostate cancer development in Saudi Arabia. Asian J Urol 2024 Jan; 11(1): 26-32.
[http://dx.doi.org/10.21203/rs.3.rs-18257/v1]
[28]
Oskina NA, Boyarskikh UA, Lazarev AF, Petrova VD, Ganov DI, Tonacheva OG. Eds A replication study examining association of rs6983267, rs10090154, and rs1447295 common single nucleotide polymorphisms in 8q24 region with prostate cancer in Siberians Urologic Oncology: Seminars and Original Investigations. Elsevier 2014.
[http://dx.doi.org/10.1016/j.urolonc.2013.02.017]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy